Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.
Elaidi R, Harbaoui A, Beuselinck B, Eymard JC, Bamias A, De Guillebon E, Porta C, Vano Y, Linassier C, Debruyne PR, Gross-Goupil M, Ravaud A, Aitelhaj M, Marret G, Oudard S. Elaidi R, et al. Among authors: de guillebon e. Ann Oncol. 2015 Feb;26(2):378-85. doi: 10.1093/annonc/mdu552. Epub 2014 Dec 1. Ann Oncol. 2015. PMID: 25467013 Free article.
Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration.
Bamias A, Tzannis K, Beuselinck B, Oudard S, Escudier B, Diosynopoulos D, Papazisis K, Lang H, Wolter P, de Guillebon E, Stravodimos K, Chrisofos M, Fountzilas G, Elaidi RT, Dimopoulos MA, Bamia C. Bamias A, et al. Among authors: de guillebon e. Br J Cancer. 2013 Jul 23;109(2):332-41. doi: 10.1038/bjc.2013.341. Epub 2013 Jun 27. Br J Cancer. 2013. PMID: 23807171 Free PMC article.
Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.
Combe P, de Guillebon E, Thibault C, Granier C, Tartour E, Oudard S. Combe P, et al. Among authors: de guillebon e. Oncoimmunology. 2015 Mar 19;4(5):e1001236. doi: 10.1080/2162402X.2014.1001236. eCollection 2015 May. Oncoimmunology. 2015. PMID: 26155388 Free PMC article. Review.
Plasma CD27, a Surrogate of the Intratumoral CD27-CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma.
Benhamouda N, Sam I, Epaillard N, Gey A, Phan L, Pham HP, Gruel N, Saldmann A, Pineau J, Hasan M, Quiniou V, Nevoret C, Verkarre V, Libri V, Mella S, Granier C, Broudin C, Ravel P, De Guillebon E, Mauge L, Helley D, Jabla B, Chaput N, Albiges L, Katsahian S, Adam J, Mejean A, Adotevi O, Vano YA, Oudard S, Tartour E. Benhamouda N, et al. Among authors: de guillebon e. Clin Cancer Res. 2022 Nov 14;28(22):4983-4994. doi: 10.1158/1078-0432.CCR-22-0905. Clin Cancer Res. 2022. PMID: 36067339
Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial.
de Guillebon E, Jimenez M, Mazzarella L, Betsou F, Stadler P, Peták I, Jeannot E, Chanas L, Servant N, Marret G, Duso BA, Legrand F, Kornerup KN, Bernhart SH, Balogh G, Dóczi R, Filotás P, Curigliano G, Bièche I, Guérin J, Dirner A, Neuzillet C, Girard N, Borcoman E, Larbi Chérif L, Tresca P, Roufai DB, Dupain C, Scholl S, André F, Fernandez X, Filleron T, Kamal M, Le Tourneau C. de Guillebon E, et al. ESMO Open. 2021 Jun;6(3):100106. doi: 10.1016/j.esmoop.2021.100106. Epub 2021 Apr 14. ESMO Open. 2021. PMID: 33865192 Free PMC article. Review.
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.
Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, Saldmann A, Gey A, Oudard S, Tartour E. Granier C, et al. Among authors: de guillebon e. ESMO Open. 2017 Jul 3;2(2):e000213. doi: 10.1136/esmoopen-2017-000213. eCollection 2017. ESMO Open. 2017. PMID: 28761757 Free PMC article. Review.
Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+ T cells.
Hasmim M, Badoual C, Vielh P, Drusch F, Marty V, Laplanche A, de Oliveira Diniz M, Roussel H, De Guillebon E, Oudard S, Hans S, Tartour E, Chouaib S. Hasmim M, et al. Among authors: de guillebon e, de oliveira diniz m. BMC Cancer. 2013 Dec 11;13:592. doi: 10.1186/1471-2407-13-592. BMC Cancer. 2013. PMID: 24330498 Free PMC article.
Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.
Roussel H, De Guillebon E, Biard L, Mandavit M, Gibault L, Fabre E, Antoine M, Hofman P, Beau-Faller M, Blons H, Danel C, Barthes FLP, Gey A, Granier C, Wislez M, Laurent-Puig P, Oudard S, Bruneval P, Badoual C, Cadranel J, Tartour E. Roussel H, et al. Among authors: de guillebon e. Oncoimmunology. 2017 Feb 21;6(4):e1286437. doi: 10.1080/2162402X.2017.1286437. eCollection 2017. Oncoimmunology. 2017. PMID: 28507793 Free PMC article.
[PD-1 and PDL-1 expression in cancer: significance and prognostic value].
Badoual C, Combe P, Gey A, Granier C, Roussel H, De Guillebon E, Oudard S, Tartour E. Badoual C, et al. Among authors: de guillebon e. Med Sci (Paris). 2013 Jun-Jul;29(6-7):570-2. doi: 10.1051/medsci/2013296005. Epub 2013 Jul 12. Med Sci (Paris). 2013. PMID: 23859507 Free article. French. No abstract available.
18 results